Soltis Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$7.32M Sell
33,669
-408
-1% -$90.5K 0.46% 54
2025
Q4
$7.79M Buy
34,077
+12,096
+55% +$2.76M 0.51% 44
2025
Q3
$5.09M Sell
21,981
-277
-1% -$56.4K 0.35% 69
2025
Q2
$4.13M Buy
22,258
+1,910
+9% +$355K 0.32% 79
2025
Q1
$4.26M Sell
20,348
-288
-1% -$56K 0.38% 73
2024
Q4
$3.67M Sell
20,636
-26,822
-57% -$4.93M 0.34% 83
2024
Q3
$9.37M Sell
47,458
-765
-2% -$143K 0.92% 19
2024
Q2
$8.27M Buy
48,223
+28,649
+146% +$4.75M 0.88% 21
2024
Q1
$3.56M Buy
19,574
+1
+0% +$172 0.4% 84
2023
Q4
$3.03M Sell
19,573
-757
-4% -$110K 0.34% 88
2023
Q3
$3.03M Buy
20,330
+540
+3% +$79.3K 0.39% 81
2023
Q2
$2.67M Buy
19,790
+233
+1% +$34.2K 0.31% 88
2023
Q1
$3.12M Buy
19,557
+1,383
+8% +$211K 0.4% 73
2022
Q4
$2.94M Buy
18,174
+382
+2% +$58.6K 0.39% 73
2022
Q3
$2.39M Buy
17,792
+171
+1% +$24.5K 0.36% 77
2022
Q2
$2.7M Buy
17,621
+909
+5% +$139K 0.39% 72
2022
Q1
$2.71M Buy
16,712
+181
+1% +$26.3K 0.38% 66
2021
Q4
$2.24M Sell
16,531
-8
-0% -$945 0.32% 70
2021
Q3
$1.78M Buy
16,539
+162
+1% +$18.5K 0.28% 78
2021
Q2
$1.84M Sell
16,377
-6
-0% -$676 0.29% 71
2021
Q1
$1.77M Buy
16,383
+50
+0.3% +$5.35K 0.32% 62
2020
Q4
$1.75M Sell
16,333
-122
-0.7% -$11.7K 0.32% 54
2020
Q3
$1.44M Buy
16,455
+14,232
+640% +$1.34M 0.34% 58
2020
Q2
$218K Buy
+2,223
New +$196K 0.06% 170

Other funds holding ABBV

Soltis Investment Advisors's ABBV Position: Q1 2026 in Review

Soltis Investment Advisors reduced its AbbVie (ABBV) stake by 1.2% in Q1 2026, selling an estimated $90.5K and leaving 33,669 shares worth $7.32M. The position accounts for 0.46% of the portfolio, ranked #54.

Soltis Investment Advisors first reported a position in ABBV in Q2 2020 and has held it in 24 quarters since. The position peaked at $9.37M in Q3 2024. 4,080 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Soltis Investment Advisors held 33,669 shares of AbbVie worth $7.32M as of Q1 2026.
  • Soltis Investment Advisors sold 408 AbbVie shares in Q1 2026, an estimated $90.5K.
  • AbbVie made up 0.46% of Soltis Investment Advisors's portfolio in Q1 2026, its #54 holding.
  • Soltis Investment Advisors first reported a position in AbbVie in Q2 2020 and has held it in 24 quarters since.
  • Soltis Investment Advisors's AbbVie position peaked at $9.37M in Q3 2024.
  • 4,080 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Soltis Investment Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.